

Supporting Information

Effective treatment of SSTR2 positive small cell lung cancer using ^{211}At -containing targeted α -particle therapy agent which promotes endogenous anti-tumor immune response

Shanshan Qin^{1,2,†}, Yuanyou Yang^{3,†}, Jiajia Zhang^{1,2}, Yuzhen Yin^{1,2}, Weihao Liu³, Han Zhang^{1,2}, Xin Fan^{1,2}, Mengdie Yang^{1,2}, Fei Yu^{1,2,*}

¹Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Yan-chang-zhong Road, Shanghai 200072, People's Republic of China

²Institute of Nuclear Medicine, Tongji University School of Medicine, No. 301 Yan-chang-zhong Road, Shanghai 200072, People's Republic of China

³Key Laboratory of Radiation Physics and Technology, Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu 610064, People's Republic of China

*Correspondence: yufei_021@163.com

†These authors contributed equally to the work.

Corresponding Author

Fei Yu - Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301 Yan-chang-zhong Road, Shanghai 200072, People's Republic of China;

Email: yufei_021@163.com

Contents

Figure S1. HPLC chromatograms of a mixture of octreotide, m-MeATE and Oct-m-MeATE conjugate.




Figure S1. HPLC chromatograms. The peaks of octreotide, m-MeATE and Oct-m-MeATE conjugate correspond to 2.28min, 2.76min and 3.13min, respectively.